---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-292939"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2022-11-28T23:59:59+00:00"
generated_at: "2026-06-21T12:41:12.070661+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Selecta Biosciences appoints Blaine Davis as CFO, replacing Kevin Tan

## Summary
- Blaine Davis named CFO effective Nov 28, 2022; Kevin Tan stepped down amicably.
- Davis receives $440,000 base salary, 40% target bonus, and option for 1,250,000 shares vesting over 4 years.
- Tan receives full 2022 bonus and equity vesting through Jan 4, 2023 per separation agreement.
- Davis previously CFO at Protara Therapeutics; over 25 years biopharma finance experience.
- Company highlights upcoming Phase 3 gout readout, Phase 1/2 MMA trial, and IL-2 candidate selection.

## SEC filing metadata
- accession: 0001193125-22-292939
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2022-11-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000119312522292939/0001193125-22-292939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000119312522292939/d405812d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-292939
- JSON: https://secwatch.observer/filing/0001193125-22-292939.json
- Plain text: https://secwatch.observer/filing/0001193125-22-292939.txt

## Key facts
- Executive change
  Blaine Davis was appointed as Chief Financial Officer at Cartesian Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On November 22, 2022, the Board of Directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”) appointed Blaine Davis as the Company’s Chief Financial Officer, effective upon the commencement of Mr. Davis’s full-time employment with the Company on November 28, 2022 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000119312522292939/0001193125-22-292939-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.